Validation of a novel integral disease index for evaluating the grade of activity in Mexican patients with ulcerative colitis: A prospective cohort study

• Published in: Revista de gastroenterología de México 2019-07, Vol.84 (3), p.317
• Main Authors: Yamamoto-Furusho, J K, Bozada-Gutiérrez, K E, Sánchez-Rodríguez, A, Bojalil-Romano, F, Barreto-Zuñiga, R, Martínez-Benitez, B
• Format: Article
• Language: eng ; spa
• Subjects: Adult; Aged; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - therapeutic use; C-Reactive Protein - analysis; Cohort Studies; Colitis, Ulcerative - diagnosis; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - pathology; Colonoscopy; Defecation; Female; Hemoglobins - analysis; Humans; Male; Mexico; Middle Aged; Prospective Studies; Reproducibility of Results; Serum Albumin - analysis
• ISSN: 0375-0906
• DOI: 10.1016/j.rgmx.2018.07.006

Ulcerative colitis is a chronic condition characterized by inflammation affecting the colon. To objectively and integrally measure disease activity in patients with ulcerative colitis and thus optimize pharmacologic treatment, a novel integral disease index was created that includes the clinical, biochemical, endoscopic, and histologic characteristics necessary for achieving that task. The aim of the present study was to validate the novel integral disease index in patients with ulcerative colitis. A cohort study on a total of 222 patients with histologic confirmations of ulcerative colitis diagnosis was conducted. The variables included in the disease index were: number of bowel movements per day; values for hemoglobin, high-sensitivity C-reactive protein, and serum albumin; and endoscopic and histologic findings measured through the subscales of the Mayo and Riley scores, respectively. The data analysis was performed utilizing the STATA SE 11.1 statistics program. The correlation of the novel disease index was very good (r=0.817, p